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Background
Experiments were designed based on the hypothesis that
recombinant vaccine constructs can focus the immune
response on shared HIV-1 neutralizing epitopes, and that
if not diverted by other biologically irrelevant epitopes,
high titers of cross-clade neutralizing antibodies (ccNAbs)
will be induced. Indeed, previous experiments showed
that when the immune response was focused on V3,
ccNAbs were induced (Zolla-Pazner et al, Virology, 2008).
Methods
A prime/boost regimen was used in which rabbits were
primed (3×) with clade C gp120 DNA and boosted (2×)
with: 1) a fusion protein in which the consensus clade C
V3 sequence was fused to the C-terminus of MuLV gp70
(V3-gp70), or 2) the same V3 sequence was inserted into
a structurally compatible site on cholera toxin B (V3-
CTB). Sera were tested for neutralizing activity in TZM-bl
cells against a panel of primary isolates and a selection of
Tier 1, Tier 2 clade B, and Tier 2 clade C pseudoviruses
(psVs) from the standard panel.
Results
Sera from rabbits boosted with V3-CTB neutralized four
primary isolates from clades A, AG and B with higher 50%
neutralizing titers (NT50) than sera from V3-gp70-
boosted rabbits. For example, sera from all five V3-CTB
rabbits neutralized Bx08 (with a geometric mean titer
[GMT50] = 1:153) whereas only one of five V3-gp70 rab-
bit responded (1:11). Similarly, serum titers in response
to V3-CTB were greater than those to V3-gp70 against 4/4
Tier 1 clade B and C psVs (GMT50 = 1:188 vs. 1:60 for V3-
gp70-immunized rabbits). Tier 2 clade C psVZM109F was
also neutralized by sera from V3-CTB rabbits (GMT50 =
~1:20).
Conclusion
A prime/boost vaccine regimen using gp120 DNA and V3-
scaffold protein immunogens induced ccNAbs. A newly
designed V3-CTB protein boost induced the strongest
ccNAb response.
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